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HYPOTHESIS SPECIAL ISSUE: CELL BIOLOGY OF THE IMMUNE SYSTEM
Membrane trafficking as an active regulator of constitutively
secreted cytokines
Natalia H. Revelo1, Martin ter Beest1 and Geert van den Bogaart1,2,*
ABSTRACT
Immune-cell activation by inflammatory stimuli triggers the
transcription and translation of large amounts of cytokines. The
transport of newly synthesized cytokines to the plasma membrane by
vesicular trafficking can be rate-limiting for the production of these
cytokines, and immune cells upregulate their exocytic machinery
concomitantly with increased cytokine expression in order to cope
with the increasing demand for trafficking. Whereas it is logical that
trafficking is rate-limiting for regulated secretion where an intracellular
pool of molecules is waiting to be released, the reason for this is not
obvious for constitutively secreted cytokines, such as interleukin-6
(IL-6), interleukin-12 (IL-12) and tumor necrosis factor-α (TNF-α).
These constitutively secreted cytokines are primarily regulated at the
transcriptional and/or translational level but mounting evidence
presented here shows that cells might also increase or decrease
the rate of post-Golgi cytokine trafficking to modulate their production.
Therefore, in this Hypothesis, we ask the question: why is there a
need to limit the trafficking of constitutively secreted cytokines? We
propose a model where cells monitor and adjust their production rate
of cytokines by sensing the intracellular level of cytokines while they
are in transit to the plasmamembrane. This self-regulation of cytokine
production could prevent an overshooting response of acute-phase
cytokines, such as IL-6, IL-12 and TNF-α, upon acute infection.
KEY WORDS: Cytokine secretion, Exocytosis, Interleukin 6,
Membrane trafficking
Introduction
Cells release hormones, cytokines, growth factors and
neurotransmitters through either regulated or constitutive secretion
(Fig. 1; see also Stanley and Lacy, 2010). In regulated secretion, an
external stimulus triggers release of molecules from intracellular
storage granules, such as insulin-containing pancreatic β-granules or
neurotransmitter-containing synaptic vesicles. The final trafficking
step of regulated secretion, the fusion of the storage granules with the
plasma membrane, is well-understood to be the bottleneck for release
(Stanley and Lacy, 2010). In constitutive secretion, there is no long-
term intracellular storage of the secreted molecules. Instead, release is
primarily regulated at the transcriptional and/or translational level,
after a stimulus triggers the biosynthesis of the molecules destined for
secretion. These newly formed molecules are then continuously
secreted, thus without the need for a second stimulus, by constitutive
trafficking through the endoplasmic reticulum (ER), the Golgi
complex and the endosomal network to the plasma membrane
(Stanley and Lacy, 2010). Nevertheless, evidence shows that
trafficking can be rate-limiting for the release of constitutively
secreted cytokines from immune cells. In this Hypothesis, we discuss
potential mechanisms of how and why this is the case. We propose
that newly synthesized interleukin 6 (IL-6) and other acute-phase
cytokines encounter their receptors in recycling endosomes while in
transit to the plasma membrane, whereas extrinsic foreign IL-6 is
endocytosed and signals from the same intracellular compartments.
This could enable the cell to monitor and compare its rate of IL-6
secretion and the outside concentration of IL-6, and adapt the
transcription of cytokines accordingly. Such negative feedback
signaling of newly synthesized cytokines might act to limit the
immune response during acute infections in order to prevent sepsis.
Trafficking is rate-limiting for constitutive secretion
of cytokines
The best-characterized pathways of constitutive secretion are for the
acute-phase inflammatory cytokines interleukins 6 and 12 (IL-6 and
IL-12, respectively) and tumor necrosis factor alpha (TNF-α) in
macrophages and dendritic cells. For all three cytokines, immune-
cell activation by inflammatory stimuli, such as the pathogenic
stimulus lipopolysaccharide (LPS), results in a rapid upregulation of
transcription and translation (Chiaruttini et al., 2016; Raabe et al.,
1998; Tanaka et al., 2016). Following co-translational import in the
ER, newly formed IL-6 is trafficked through the Golgi complex to a
pool of recycling endosomes that contain the vesicle-associated
membrane protein 3 (VAMP3) – a soluble N-ethyl maleimide-
sensitive factor (NSF) attachment protein (SNAP) receptor
(SNARE) protein – before it is finally secreted at the plasma
membrane (Fig. 2; see also Manderson et al., 2007; Murray et al.,
2005b; Verboogen et al., 2018a). TNF-α is secreted through the
same pathway (Manderson et al., 2007; Murray et al., 2005a,b;
Shurety et al., 2000) but is synthesized as a precursor that is
membrane-anchored through a transmembrane helix that is cleaved
off by metalloproteases at the plasma membrane (Moss et al., 1997).
IL-12 is assembled in the ER as a heterodimer of its p35 and p40
subunits, and is trafficked to the plasma membrane via the Golgi
complex and late endosomal and/or lysosomal compartments that
contain the SNARE protein VAMP7 (Chiaruttini et al., 2016).
Although primarily being regulated at the biosynthesis level
(Chiaruttini et al., 2016; Raabe et al., 1998; Tanaka et al., 2016),
mounting evidence suggests that post-Golgi trafficking can be rate-
limiting for the secretion of IL-6, IL-12 and TNF-α. Thus, in order
to cope with the increasing demand for cytokine production in
response to pathogenic stimuli, immune cells upregulate their
trafficking machinery at both the transcriptional and translational
level, as well as at the post-translational level. As a consequence,
activated dendritic cells increase the delivery rate of IL-6-containingReceived 6 June 2019; Accepted 19 August 2019
1Tumor Immunology Lab, Radboud University Medical Center, Radboud Institute
for Molecular Life Sciences, 6500HB Nijmegen, The Netherlands. 2Department of
Molecular Immunology, Groningen Biomolecular Sciences and Biotechnology
Institute, University of Groningen, 9747AG Groningen, The Netherlands.
*Author for correspondence (g.van.den.bogaart@rug.nl)
G.v.d.B., 0000-0003-2180-6735
1













vesicles at the plasma membrane about two-fold, as shown by
quantitative imaging (Verboogen et al., 2018b). At the post-
translational level, the SNARE protein syntaxin-3, which is
involved in IL-6 release, moves from intracellular compartments
to the plasma membrane in LPS-activated macrophages (Collins
et al., 2014). Moreover, Förster resonance energy transfer (FRET)
coupled to fluorescence lifetime imaging microscopy (FLIM)
revealed that LPS activation of dendritic cells results in increased
formation of the complex between the SNARE protein VAMP3 –
which is also involved in IL-6 release – and syntaxin-4 at the plasma
membrane (Verboogen et al., 2017). At transcriptional and
translational levels, the expression of SNAREs and many other
proteins involved in trafficking of cytokines is upregulated in
activated macrophages and dendritic cells (Chiaruttini et al., 2016;
Collins et al., 2014; Manderson et al., 2007; Mori et al., 2011;
Murray et al., 2005a; Pagan et al., 2003). Although not directly
proven, this is likely to result in an increased rate of exocytic
trafficking that is required to secrete all the newly synthesized
cytokines.
Despite this upregulation of trafficking, evidence indicates that
there is no or only little surplus capacity of trafficking, and the
transport of newly synthesized cytokines to the plasmamembrane can
still be an apparent bottleneck for cytokine production in activated
immune cells. First, RNA interference (RNAi) to partially knock
down golgin p230 (officially known as Golga4), a long coiled-coil
protein residing at the trans-Golgi network and required for export of
TNF-α from the Golgi, leads to reduced TNF-α secretion (Lieu et al.,
2008). Similarly, TNF-α release from recycling endosomes at the
plasma membrane is sensitive to the levels of proteins orchestrating
this process, as shown for the SNARE proteins VAMP3, syntaxin-4,
syntaxin-6 and Vti1b, and the small GTPase Rab37 (Mori et al.,
2011; Murray et al., 2005a,b; Pagan et al., 2003). Interestingly, not
only does their downregulation by RNAi or the overexpression of
dominant-negative mutants lead to reduced secretion of TNF-α – but
their overexpression has the opposite effect (Mori et al., 2011;Murray
et al., 2005a,b; Pagan et al., 2003), indicating that the levels of these
trafficking proteins can still be rate-limiting for secretion. Second,
post-Golgi trafficking of IL-6 is mediated by the SNARE proteins
VAMP3, syntaxin-3, syntaxin-6 and Vti1b, and their overexpression
increases IL-6 production, whereas its knockdown following RNAi
results in a reduction of IL-6 release (Collins et al., 2014; Manderson
et al., 2007; Verboogen et al., 2017). Finally, for IL-12, its secretion
from late endosomal and/or lysosomal compartments is sensitive to
the levels of VAMP7, because knockout or knockdown of VAMP7
leads to reduced IL-12 secretion (Chiaruttini et al., 2016). These data
show that, although the exocytic pathway is upregulated upon
immune-cell activation, trafficking can still be rate-limiting for the
release of IL-6, IL-12 and TNF-α, even though these cytokines
are constitutively secreted and are primarily regulated at the
transcriptional and/or translational level (Chiaruttini et al., 2016;
Raabe et al., 1998; Tanaka et al., 2016). These findings point to a
conundrum: why is there a need for this apparent bottleneck?
Mechanisms underlying rate-limiting trafficking of
constitutively secreted cytokines
There are two possible mechanisms that explain how trafficking can
be rate-limiting for constitutive cytokine secretion. First, it is
possible that the trafficking machinery cannot cope with high levels
of protein transcription and/or translation. Indeed, after LPS
stimulation of macrophages and dendritic cells, newly synthesized
intracellular IL-6, IL-12 and TNF-α become visible at the
perinuclear Golgi area where they reach maximum concentrations
∼2–4 h after stimulation (Chiaruttini et al., 2016; Manderson et al.,
2007; Murray et al., 2005b; Shurety et al., 2000; Verboogen et al.,
2018b), suggesting a possible accumulation of these cytokines in
the Golgi complex at early time points after stimulation. It is also
possible that newly synthesized cytokines are degraded in
lysosomes and/or through the ER-associated degradation (ERAD).
Support that post-Golgi trafficking might be rate-limiting for
secretion of TNF-α (and other highly produced secretory proteins)
comes from experiments with the retention using selective hooks
(RUSH) system (Boncompain et al., 2012). The RUSH system is
based on the reversible retention of recombinantly expressed GFP-
tagged TNF-α in the ER through a streptavidin-binding protein that
anchors to a stable ER ‘hook protein’ that is tagged with






















Fig. 1. Regulated versus constitutive secretion.
(A) Regulated secretion. After its transcription and
translation, a protein accumulates in storage granules. Upon
arrival of a stimulus, these storage granules fuse with the
plasma membrane resulting in exocytosis. Exocytosis is,
thus, rate-limiting for secretion (red arrow). (B) Constitutive
secretion. A stimulus upregulates transcription and/or
translation of a factor that, after its de novo synthesis and
trafficking to the plasma membrane, is continuously
secreted. Here, transcription and/or translation are rate-
limiting for secretion (red arrow).
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the rapid release of the GFP-tagged TNF-α from this hook protein
and triggers the synchronous transport of TNF-α molecules via the
secretory pathway, which can be visualized by microscopy
(Boncompain et al., 2012). After biotin addition, TNF-α (and
other secretory cargoes) rapidly leaves the ER and accumulates at
the Golgi region where it reaches peak levels ∼10 min after biotin
addition. Although the first TNF-α already reaches the plasma
membrane within minutes after ER release, it takes a further
20–30 min until all TNF-α has left the Golgi complex and reached
the plasma membrane (Boncompain et al., 2012). Thus, trafficking
from the Golgi to the plasma membrane is slower than trafficking
from the ER to the Golgi. Accordingly, when the rate of cytokine
synthesis is faster than post-Golgi trafficking, cytokines accumulate
in the Golgi region, just as observed for IL-6, IL-12 and TNF-α 2–4
h after immune-cell activation (Chiaruttini et al., 2016; Manderson
et al., 2007; Murray et al., 2005b; Shurety et al., 2000; Verboogen
et al., 2018b). However, at later timepoints, the immune cells might
have sufficiently upregulated their trafficking machinery because
accumulation in the Golgi complex is no longer observed
(Chiaruttini et al., 2016; Manderson et al., 2007; Murray et al.,
2005b; Shurety et al., 2000; Verboogen et al., 2018b). Therefore, the
accumulation of cytokines at the Golgi cannot explain why
overexpression of trafficked proteins results in increased cytokine
secretion at these later timepoints of immune-cell activation
(Manderson et al., 2007; Mori et al., 2011; Murray et al., 2005a,
b; Pagan et al., 2003). An open question is whether this transient
accumulation of cytokines at the Golgi is just a non-functional
consequence because the trafficking pathway is unable to cope with
the high rate of cytokine synthesis or whether it has any functional
role in cytokine signaling.
The second explanation of how trafficking can be rate-limiting for
protein secretion is that intracellular trafficking might somehow
affect the biosynthesis of cytokines, so that cells sense their rate of
cytokine production; this might provide a negative feedback
mechanism for their biosynthesis (Fig. 2). At least for IL-6,
current data provide evidence for this second mechanism. First,
quantitative imaging performed by our group has shown that single
secretory vesicles contain only a few IL-6 molecules in LPS-
activated dendritic cells (Verboogen et al., 2018b); moreover, given
the thousands of insulin molecules observed in pancreatic β-vesicles
(Michael et al., 2007), it is unlikely that these few molecules reflect
capacity limits of the secretory vesicles. Second, macrophages and
dendritic cells contain the receptors for IL-6, IL-12 and TNF-α,
which makes them prone to so-called autocrine signaling, whereby
cells respond to the same cytokine they produce (Fukao et al., 2001;
Parameswaran and Patial, 2010; Verboogen et al., 2018a). For the
IL-6 receptor, we have recently shown that more than half of its
signaling occurs from within recycling endosomes because only
∼40% of IL-6 receptors reside at the plasma membrane, with the
remainder being located within endosomes and the Golgi complex
(Verboogen et al., 2018a). Furthermore, blockage of IL-6 uptake
either by using the dynamin inhibitor dynasore or by overexpression
of a dominant-negative mutant of the endocytic cargo adapter epsin
2, significantly inhibited activation of its downstream factor signal
transducer and activator of transcription 3 (STAT3) by ∼60%
(Verboogen et al., 2018a). To enable endosomal signaling, IL-6 has
to be endocytosed prior to activating the IL-6 receptor from within
the lumen of endosomal compartments. Thus, these recycling
endosomes have to contain the IL-6 receptor (Verboogen et al.,
2018a) but – similar to the recycling endosomes encountered by
newly synthesized IL-6 during its trafficking from the Golgi to the
plasma membrane – they also contain VAMP3 (Manderson et al.,
2007; Murray et al., 2005b; Verboogen et al., 2018a). In fact, we
have shown that both newly synthesized IL-6 in transit to the plasma
membrane and endocytosed exogenous IL-6 signal from within
recycling endosomes of the same signature, and are able to activate
STAT3 downstream of the IL-6 receptor (Verboogen et al., 2018a).
Although STAT3 has pro-inflammatory effects, it inhibits activation
of dendritic cells and its signaling results in a reduced transcription
of the IL6 gene (Fig. 2) (Bode et al., 2012; Melillo et al., 2010). This
negative feedback inhibition of IL-6 synthesis is present for the first
hours after LPS stimulation (Verboogen et al., 2018a). At sustained
periods of LPS exposure, the increased expression of suppressor of
cytokine signaling 3 (SOCS3) switches off IL-6 signaling (Bode
et al., 2012; Croker et al., 2012), thereby inhibiting this negative
feedback loop and allowing for an increase in IL-6 transcription
(Bode et al., 2012; Verboogen et al., 2018a). SOCS3 is a well-
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Fig. 2. Trafficking regulates the production of the
constitutively secreted cytokine IL-6. (A) Proposed
mechanism for the self-limiting production of IL-6. Both
endocytosed and newly synthesized IL-6 molecules bind
to the IL-6 receptor that resides in recycling endosomes.
This, in turn, leads to signaling and activation of the
transcription factor STAT3, its translocation to the nucleus
and the downregulation of IL6 transcription. Through
this mechanism, immune cells might monitor their rate of
IL-6 production, compare it to the outside concentration of
IL-6 to adjust their rate of IL-6 synthesis and prevent an
overshooting cytokine response. (B) Potential
mechanism explaining how trafficking can be a bottleneck
for IL-6 production. Upon a perturbation of trafficking (e.g.
by using RNAi to knock down an exocytic SNARE protein)
IL-6 accumulates in recycling endosomes where it binds
to the IL-6 receptor, resulting in increased activation of
STAT3. This, in turn, leads to stronger inhibition of IL6
transcription, thus, eventually shutting down IL-6
synthesis and, therefore, secretion.
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2012; Croker et al., 2012), and micewith impaired SOCS3 signaling
develop IL-6-related inflammatory diseases (Croker et al., 2004).
Taken together, these data, thus, show how endosomal signaling
(Irannejad et al., 2015; Lobingier and von Zastrow, 2019; Murphy
et al., 2009; Platta and Stenmark, 2011) allows dendritic cells to sense
both their production rate of IL-6 and the extracellular concentration
of IL-6. This mechanism makes it possible for cells to self-limit their
production of IL-6 during the first hours after encountering a
pathogenic stimulus (Verboogen et al., 2018a). Such a regulation of
IL-6 production explains how trafficking can be an apparent
bottleneck for the production of the constitutively expressed
cytokine IL-6. If the rate of IL-6 release is reduced (for instance,
due to knockdown of a SNARE), IL-6 spends more time within
recycling endosomes, enabling prolonged activation of STAT3 and
reduced transcription of IL6. By contrast, when the trafficking rate is
increased (for instance, due to overexpression of a SNARE), IL-6
spends less time in recycling endosomes, leading to reduced
activation of STAT3 and increased IL6 expression. This model,
thus, can explain why, in cell culture, increasing or reducing IL-6
trafficking by overexpression or knockdown of the SNARE proteins
VAMP3, syntaxin-3, syntaxin-6 and Vti1b results in increased or
reduced production of IL-6, respectively (Collins et al., 2014;
Manderson et al., 2007; Verboogen et al., 2017). Importantly, there is
in vivo evidence supporting such a negative feedback for IL-6
production. Mice with conditional knockout of the IL-6 receptor in
liver cells show increased IL-6 secretion and higher blood levels of
IL-6 (Klein et al., 2005; Wunderlich et al., 2010). In addition,
increased serum levels of IL-6 have been observed upon antibody
therapy against the IL-6 receptor in patients with rheumatoid arthritis
or other auto-immune diseases (Nishimoto et al., 2008; Shimamoto
et al., 2013); although, in both cases, these findings might also be
explained by reduced removal of IL-6 from the circulation by the
liver. The negative feedback loop of IL-6 signaling potentially also
limits the production of other cytokines, including TNF-α and IL-12
(Bode et al., 2012; Xing et al., 1998). Moreover, unpublished
observations obtained in our laboratory show that production of IL-12
might be self-limited in a manner similar to that described for IL-6
here (our unpublished observations). We thus propose that immune
cells monitor the release rate and extracellular concentration of
cytokines, and use this information to adjust their de novo synthesis,
thereby enabling a self-limitation of their cytokine production. This,
however, raises the question why cells would need to transiently
self-limit their production of cytokines.
Why is there a need to limit the trafficking rate for
constitutive secretion?
A balanced production of acute-phase cytokines is important for the
induction and propagation of the immune response to acute
infections, as well as for the control of the resolution phase. The
acute systemic infection triggered by the presence of viable bacteria,
fungi or microbial products in the blood can elicit sepsis and septic
shock (Chaudhry et al., 2013; Hotchkiss et al., 2016). During sepsis,
vascular endothelial cells and immune cells produce high amounts
of acute-phase cytokines – including IL-6, IL-12 and TNF-α – in a
process called the cytokine storm (Chaudhry et al., 2013; Hotchkiss
et al., 2016; Paardekooper et al., 2017). The cytokine storm then
triggers the inflammatory immune responses that are required to
resolve infection, including activation of B and T lymphocytes,
modulation of haematopoiesis, release of hepatic acute-phase
proteins – such as C-reactive protein – and induction of fever
(Chaudhry et al., 2013; Hotchkiss et al., 2016). However, an
excessive inflammatory response can lead to tissue damage and
organ failure because of insufficient blood flow to one or more
organs caused by low blood pressure, to lactic acidosis or to reduced
urine production (Chaudhry et al., 2013; Hotchkiss et al., 2016).
The most-severe form of sepsis is septic shock – the main cause of
death in intensive care units (Schulte et al., 2013) – worldwide
leading to ∼5.3 million deaths annually (Hotchkiss et al., 2016).
Low serum levels of IL-6 are associated with a better prognosis for
sepsis as IL-6 levels in patients with septic shock are higher than in
patients without shock (Damas et al., 1992; Hack et al., 1989; Martí
Arjona and Moreno Camacho, 2017; Pathan et al., 2004; Spittler
et al., 2000). Indeed, plasma IL-6 shows the best correlation with
mortality rate in patients with sepsis (Hack et al., 1989; Kumar et al.,
2009;Martí Arjona andMoreno Camacho, 2017). This is also true for
animal models. Compared to wild-type mice, LPS administration in
IL-6-knockout mice led to reduced inflammatory responses and
protection against mortality and organ failure (Cuzzocrea et al., 1999;
Remick et al., 2005). Therefore, it might be beneficial to limit the
levels of acute-phase cytokines upon acute infection, particularly
those of IL-6. The production of appropriate levels of IL-6 and other
acute-phase cytokines is very important for triggering an adequate
immune response while preventing septic shock; however, their
expression is strictly controlled at different levels, including
access to their promoter region, regulation of transcription and
posttranscriptional modifications (Tanaka et al., 2016). We now
propose that these mechanisms of regulation of IL-6 production are,
in turn, controlled by negative feedback signaling from the pool of
IL-6 residing within recycling endosomes, which consists of a
combination of newly synthesized IL-6 in transit to the plasma
membrane and endocytosed IL-6 from the outside of the cell. This
negative feedback control could prevent an overshooting response
that could have devastating consequences upon acute systemic
infection. As the rate of exocytosis determines the time IL-6 spends
within recycling endosomes, the trafficking rate of IL-6 might
directly correlate with the extent of this negative feedback signaling,
which can explain how trafficking is an apparent bottleneck for
cytokine secretion. However, the existence of this self-limiting
mechanism of IL-6 production and its potential contribution in
preventing septic shock still needs to be formally proven, for instance
by using LPS injections in mice with conditional knockout for the
IL-6 receptor in those cells that produce IL-6.
Conclusions
In this Hypothesis, we propose a mechanism of how trafficking can
be both an apparent bottleneck and a regulator of the production of the
constitutively secreted cytokines IL-6, IL-12 and TNF-α. We suggest
that newly synthesized cytokines signal from within recycling
endosomes while they are in transit to the plasma membrane.
Extracellular IL-6 is also endocytosed by the cell and signals from
within the same recycling endosomes. The signals from newly
synthesized cytokines are, thereby, likely to be combined with the
signals from extracellular cytokines (autocrine signaling), allowing
the cell to adapt its IL-6 production rate depending on the
extracellular concentration of IL-6. As the exocytosis rate directly
influences the level of cytokines residing within intracellular
compartments, our model explains why trafficking can be rate-
limiting for the release of IL-6 and other cytokines, even though they
are primarily regulated at the transcriptional and/or translational level.
The self-limiting production of IL-6 is transient and is switched off at
longer activation times through IL-6-induced expression of SOCS3.
With regard to a possible reason for why cells would transiently
self-limit their production of IL-6, IL-12 and TNF-α, we suggest that
this prevents an overshooting response of these acute-phase cytokines
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upon acute infection, which would lower the risk of sepsis and septic
shock.
The monitoring of production rates might not only be limited to
the examples we discussed here, but could also occur for other
constitutively secreted molecules. This seems possible because many
(if not all) cells that produce a particular cytokine, hormone or growth
factor also express the receptor for this molecule, which is a
prerequisite for self-signaling. Moreover, signaling within
intracellular compartments has now been observed for many
different molecules, including epidermal growth factor (EGF), Wnt
signals and ligands of Toll-like receptors (Irannejad et al., 2015;
Lobingier and von Zastrow, 2019; Murphy et al., 2009; Platta and
Stenmark, 2011), raising the possibility that their production rates are
monitored in a way similar to that we propose here. Intracellular
signaling of newly synthesized cytokines might not be restricted to
cytokines that are released by canonical ER–Golgi vesicular
trafficking but might also occur for non-conventionally released
cytokines, such as interleukin-1 beta (IL-1β). IL-1β is a cytosolic
protein that is released from immune cells through an incompletely
understood pathway (Sitia and Rubartelli, 2018). Moreover, cells that
produce IL-1β also express both activating and inhibitory receptors
for IL-1β, including a cytosolic isoform of the inhibitory type 2 IL-1β
receptor (Peters et al., 2013), which might enable signaling of IL-1β
from the cytosol prior to release. Another open, but intriguing,
possibility is that the receptors that mediate self-signaling are also
responsible for the differential intracellular sorting of cargomolecules
to different compartments of the trafficking pathway as, for instance,
observed for IL-12 that is sorted to late endosomes (Chiaruttini et al.,
2016), and IL-6 and TNF-α that accumulate in different sub-
compartments of recycling endosomes (Manderson et al., 2007;
Murray et al., 2005b). Future studies investigating the trafficking of
constitutively secreted molecules, thus, should not only measure the
final secretion rate but, also, address their transcription and translation
levels as well as the intracellular fate of non-secreted molecules.
Taken together, we, therefore, argue that constitutive secretion is
likely to be not just the mere flux of material from the ER and Golgi
to the plasma membrane but that this trafficking route is used by the
cell to monitor protein synthesis rates and to compare this to uptake
from outside of the cell, in order to regulate and adapt protein
production.
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